Genprex, Inc. (NASDAQ:GNPX – Get Free Report) shares traded down 3.4% during trading on Friday . The stock traded as low as $0.48 and last traded at $0.48. 103,784 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 349,795 shares. The stock had previously closed at $0.50.
Genprex Price Performance
The firm has a 50-day moving average of $0.84 and a 200 day moving average of $0.99.
About Genprex
Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.
See Also
- Five stocks we like better than Genprex
- Insider Selling Explained: Can it Inform Your Investing Choices?
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- Best Stocks Under $5.00
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.
-limited-logo-1200x675.png?v=20221128134910&h=45&w=95&zc=2){kind=logo}
